News | February 04, 2022
Lupin Q3FY22 PAT at Rs 545.52 cr.
Lupin has reported consolidated financial results for the period ended December 31, 2021
Lupin has reported consolidated financial results for the period ended December 31, 2021
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
The target demographic will be those between the ages of 30 and 65 years
The objective behind introducing this extraordinary digital campaign is to spread awareness among Gen X and Z for the need of breast self-examination
Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row
Pristyn Care operates on an innovative full- stack Care Delivery model to ensure that high quality surgical care is offered to patients at an affordable cost
The need is to vaccinate people who have not contracted Covid-19
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Subscribe To Our Newsletter & Stay Updated
